Pharma companies with ESG more valuable say investors

When asked how to balance ESG with broader business goals, the panel was unanimous in its assessment that ESG is ‘good for business’

IAVI and Moderna launch first-in-Africa clinical trial of mRNA HIV vaccine

Phase I trial in Rwanda and South Africa aims to evaluate mRNA HIV vaccine antigen for safety and immunogenicity and strengthen regional scientific capacity

WHO validates Convidecia vaccine for Covid-19

The vaccine was found to have 64% efficacy against symptomatic disease and 92% against severe Covid-19

Moderna announces advancements in mRNA platform science for application across multiple diseases

Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery

Adroit BioMed launches Fortisil range of skincare products

Biological E. reduces Corbevax price to Rs.250 a dose

The move comes a few weeks after receiving the EUA for children between the ages of 5 and 12

Erectile dysfunction drugs help prevent death and complications due to heart disease

Huntington Medical Research Institutes present first-of-its-kind study examining impact of erectile dysfunction drugs on major adverse cardiovascular events and mortality

CCMB develops India’s first mRNA vaccine technology

The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere

New nirsevimab data analyses reinforce efficacy against RSV

Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose

CEPI partners with Bharat Biotech, Unversity of Sydney and ExcellGene to develop variant proof Covid-19 vaccine

CEPI will provide funding of up to US $19.3 million to support the development of a ‘variant-proof’ SARS-CoV-2 vaccine candidate to an international multidisciplinary consortium